Recombinant Biologic to Prevent & Treat AKI

• MIF-2 (aka D-DT) has utility for the prevention and repair of ischemia/reperfusion AKI.
• Validity of Human Clinical Hypothesis: Genetically characterized subset of cardiac surgery patients suffer AKI.
• Efficacy/Safety
  • Mouse: MIF-2 treatment results in AKI repair (A/B).
  • Mouse: MIF-2 stimulates multiple cell repair mechanisms. (C).
• Pre-clinical studies
  • Mouse: High therapeutic dose without toxic side effects.
  • Pig: Initial PK/PD studies completed.
• Manufacturing This 37.5 kD MIF-2 protein homotrimer (D) has been scaled up for porcine studies (CRO; E. coli).
• Innovators: Bucala, Young, Moeckel
• IP: Issued & Pending Patents